Ian has over 25 years of experience in the life sciences sector from academic research to biotech startup to big pharma. Founded Domantis Limited with Sir Gregory Winter, acquired by GSK for $454 million. He is the former Senior VP, Head of Worldwide Business Development and Head of Biopharm R&D at GSK. Now Chairman of the Stevenage Bioscience Catalyst and the Investment Committee for Apollo Therapeutics.

David has spent 20+ years in the City / US (San Francisco) across a range of investment management roles, latterly as Managing Director at Intermediate Capital Group. David came out of a full time role with ICG in Jan 2016 to concentrate full-time on angel/early-stage investing, with a focus on life sciences. He has been an angel investor for a few years, is increasingly active as a lead investor and even takes Board positions, where his financial services / investment background is of particular use to a company.

Xavier has an MBA from ESADE in Barcelona and a Masters in International Management from the University of Thunderbird in Phoenix, Arizona. He has vast experience directing companies which specialise in the banking and investment sectors. He is on the board of a large number of companies (including Capital Cell), working in the fields of technology and life sciences. Currently he is Chief Financial Officer of InKemia and has been working with them since 2002.

Joan and Jordi have worked together for over 20 years and have successfully co-founded and sold two companies for multi-million $ exits. Joan is a Senior Software Developer with experience in analysis, design, development, testing and implementation of various internet-based applications.